Efficacy and Safety Study of IBI-10090 in Patients Undergoing Cataract Surgery
| Status: | Terminated |
|---|---|
| Conditions: | Ocular |
| Therapuetic Areas: | Ophthalmology |
| Healthy: | No |
| Age Range: | 40 - Any |
| Updated: | 12/6/2018 |
| Start Date: | January 2010 |
| End Date: | June 2010 |
A Multicenter, Randomized, Double-masked, Dose-ranging, Phase 2 Study to Evaluate the Efficacy and Safety of IBI-10090 in Cataract Surgery Patients
This study will test the efficacy and safety of IBI-10090 for the reduction of ocular
inflammation after cataract surgery.
inflammation after cataract surgery.
All patients received active treatment in this study. Dose group 1 received 114ug of
dexamethasone, Dose group 2 received 513ug and Dose group 3 received 684ug.
dexamethasone, Dose group 2 received 513ug and Dose group 3 received 684ug.
Inclusion Criteria:
- Male or female patients 40 years of age scheduled for unilateral cataract surgery
(phacoemulsification or extracapsular extraction) with posterior chamber intraocular
lens implantation.
Exclusion Criteria:
- Patients who have used any ocular, topical or oral corticosteroids within 7 days prior
to Day 0.
- Patients who have used topical ocular NSAIDs in the study eye within 15 days prior to
screening.
- Patients with any signs of intraocular inflammation in either eye at screening.
- Patients who have received any prior intravitreal injections in the study eye.
We found this trial at
1
site
Click here to add this to my saved trials
